IP Library › Granted Patent US 11,530,195
Granted Patent B1
US 11,530,195 · App. 17/749,517 · Granted Dec 20, 2022

Protacs targeting coronavirus 3CL protease and preparation method and application thereof

Inventors: Chengyuan Liang (Xi'an, CN); Liang Xin (Xi'an, CN); Lei Tian (Xi'an, CN); Juan Xia (Xi'an, CN); Nan Qin (Xi'an, CN); Jingyi Li (Xi'an, CN); Taotao Qiang (Xi'an, CN); Han Li (Xi'an, CN); Xuechuan Wang (Xi'an, CN); Xiaolin Xie (Xi'an, CN); Dezhu Zhang (Xi'an, CN); Qingbo Zhao (Xi'an, CN); Zhenfeng Shi (Xi'an, CN); Min Li (Xi'an, CN); Shaojun Zhang (Xi'an, CN); Kangxiong Wu (Xi'an, CN); Catherine J Lee (Atlanta, GA); Maggie Lewis (North Decatur, GA); Zhao Ma (Xi'an, CN); Xuhua Zhou (Xi'an, CN)
Assignee: SHAANXI PANLONG PHARMACEUTICAL CO., LTD.
C07D401/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,530,195
App. No.
17/749,517
Granted
Dec 20, 2022
Kind
B1
Abstract

A compound of formula I or formula II, a pharmaceutically acceptable salt, or a tautomer thereof is disclosed. The Linker is or and n is 1-6.

Claims (8)

1. A compound of formula I or formula II, a pharmaceutically acceptable salt, or a tautomer thereof:

wherein, the Linker is

or

n and n is 1-6.

2. The compound of claim 1 , wherein the compound is selected from the group consisting of:

3. The compound of claim 1 , wherein the pharmaceutically acceptable salt comprises one selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, fumaric acid, maleic acid, oxalic acid, malonic acid, succinic acid, citric acid, malic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, glutamic acid, and aspartic acid.

4. An anti-coronavirus pharmaceutical preparation comprising the compound of claim 1 .

5. The anti-coronavirus pharmaceutical preparation of claim 4 , wherein the coronavirus is novel coronavirus SARS-CoV-2.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2022
From: LIANG, CHENGYUAN; XIN, LIANG; TIAN, LEI; XIA, JUAN; QIN, NAN; LI, JINGYI; QIANG, TAOTAO; LI, HAN; WANG, XUECHUAN; XIE, XIAOLIN; ZHANG, DEZHU; ZHAO, QINGBO; SHI, ZHENFENG; LI, MIN; ZHANG, SHAOJUN; WU, KANGXIONG; LEE, CATHERINE J; LEWIS, MAGGIE; MA, ZHAO; ZHOU, XUHUA
To: SHAANXI PANLONG PHARMACEUTICAL CO., LTD.
Reel/Frame 059971/0546 →
Priority Claims (1)
CN 202210335448.3 · Mar 31, 2022 · national
Cited By (2)
US 12,208,110 US 12,473,314